rpmjResearch'n Practical Medicine JournalResearch and Practical Medicine Journal2410-1893"QUASAR", LLC10.17709/2409-2231-2016-3-1-7rpmj-124Research ArticleОбзоры, лекцииReviews, lecturesКЛИНИЧЕСКАЯ ЗНАЧИМОСТЬ БИОЛОГИЧЕСКИХ МАРКЕРОВ ПРИ РАКЕ ЯИЧНИКОВ, РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, КОЛОРЕКТАЛЬНОМ РАКЕCLINICAL SIGNIFICANCE OF BIOMARKERS IN OVARIAN CANCER, PROSTATE CANCER, COLORECTAL CANCERМаршутинаН. В.MarshutinaN. V.

к.б.н., старший научный сотрудник отделения прогноза эффективности консервативного лечения

PhD, senior researcher, department of forecast of the effectiveness of conservative treatment

prognoz.06@mail.ruСолохинаМ. П.SolokhinaM. P.

к.б.н., научный сотрудник отделения прогноза эффективности консервативного лечения

PhD, researcher, department of forecast of the effectiveness of conservative treatment

АлентовИ. И.AlentovI. I.

младший научный сотрудник отделения прогноза эффективности консервативного лечения

junior researcher, department of forecast of the effectiveness of conservative treatment

СергееваН. С.SergeevaN. S.

д. б.н., руководитель отделения прогноза эффективности консервативного лечения МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России, профессор кафедры биологии медико- биологического факультета ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России

Professor, Dr. Sci. (Biol.),, head of the department of forecast of the effectiveness of conservative treatment, P. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, professor of biological department, medical-biological faculty of FBEI HPE "Pirogov Russian National Research Medical University" the Ministry of Health of the Russian Federation

МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России (Москва, Россия) 125284, Россия, Москва, 2-й Боткинский проезд, 3РоссияP. Hertsen Moscow Oncology Research Institute – b ranch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation (Moscow, Russia) 3, 2nd Botkinskiy proezd, Moscow, 125284, RussiaRussian FederationМНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России (Москва, Россия) 125284, Россия, Москва, 2-й Боткинский проезд, 3 ГБОУ ВПО «Российский национальный исследовательский медицинский университе т им. Н.И. Пирогова» Минздрава России (Москва, Россия) 117997, Россия, Москва, ул. Островитянова, 1РоссияP. Hertsen Moscow Oncology Research Institute – b ranch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation (Moscow, Russia) 3, 2nd Botkinskiy proezd, Moscow, 125284, Russia FBEI HPE "Pirogov Russian National Research Medical University" the Ministry of Health of the Russian Federation (Moscow, Russia) 1, ul. Ostrovityanova, Moscow, 117997, RussiaRussian Federation201625032016314657Copyright © Маршутина Н.В., Солохина М.П., Алентов И.И., Сергеева Н.С., 20162016Маршутина Н.В., Солохина М.П., Алентов И.И., Сергеева Н.С.Marshutina N.V., Solokhina M.P., Alentov I.I., Sergeeva N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpmj.ru/rpmj/article/view/124

Обзор посвящен современным представлениям о серологических опухоле-ассоциированных маркерах (ОМ) и их месте в онкологии: использование для дифференциальной диагностики, в прогнозе течения опухолевого процесса, в мониторинге, для доклинического выявления рецидивов болезни, а также в скрининге, направленном на раннее выявление злокачественных новообразований. Описаны алгоритмы использования наиболее информативных ОМ: СА125, НЕ4 (при раке яичников), ПСА и его изоформ (при раке предстательной железы), iFOBT (при колоректальном раке).

The review is devoted to modern notions about serum tumor markers and their place in oncology: using for differential diagnosis, in prognosis of course of tumor process, during follow-up, for preclinical detection of disease recurrences, as well as in screening aimed at early detection of malignant neoplasms. Algorithms of using of most informative tumor markers: CA125, HE4 (in ovarian cancer), PSA and its isoforms (in prostate cancer), iFOBT (in colorectal cancer) were described.

серологические опухолевые маркеры СА125НЕ4ПСАсвободная фракция ПСА[-2] проПСАiFOBTрак яичниковрак предстательной железыколоректальный ракserum tumor markersCA125HE4PSAfree PSA[-2]proPSAiFOBTovarian cancerprostate cancercolorectal cancerReferencesMoghadam A. F., Stieber P. Sensible use of tumor markers. 2nd ed. Basel, Jurgen-Hartmann Verlag. 1993.Moghadam A. F., Stieber P. Sensible use of tumor markers. 2nd ed. Basel, Jurgen-Hartmann Verlag. 1993.Practice Guidelines and Recommendation for use of Tumor Markers in the Clinic. The Natl. Acad. Clin. Biochem. 2002; 15; 1–56.Practice Guidelines and Recommendation for use of Tumor Markers in the Clinic. The Natl. Acad. Clin. Biochem. 2002; 15; 1–56.Сергеева Н. С., Маршутина Н. В. Серологические опухолеассоциированные маркеры. В кн.: Чиссов В. И., Давыдов М.И (ред.). Онкология. Национальное руководство. М.: ГЭОТАР-медиа, 2008.Sergeeva N. S., Marshutina N. V. Serologicheskie opukholeassotsiirovannye markery. In: Chissov V. I., Davydov M.I (eds.). Onkologiya. Natsional'noe rukovodstvo. Moscow: "GEOTAR- media" Publ., 2008. (Russian).Бережная Н. М., Чехун В. Ф. Иммунология злокачественного роста. К.: Наукова думка, 2005.Berezhnaya N. M., Chekhun V. F. Immunologiya zlokachestvennogo rosta. Kiev: "Naukova dumka" Publ., 2005. (Russian).Duffi M. J. How to validate a new cancer biomarker: from discovery to clinical application. Tumor Biology. 2014; 35 (1): 5.Duffi M. J. How to validate a new cancer biomarker: from discovery to clinical application. Tumor Biology. 2014; 35 (1): 5.Маршутина Н. В., Сергеева Н. С. Серологические опухолевые маркеры в первичной диагностике и мониторинге больных раком молочной железы. Российский онкологический журнал. 2002; 4: 45–48.Duffi M. J. How to validate a new cancer biomarker: from discovery to clinical application. Tumor Biology. 2014; 35 (1): 5.Сергеева Н. С., Русаков И. Г., Маршутина Н. В., Родина И. А., Ахмедова И. М., Кирсанова В. А., Махмурова Н. Т., Сергеева В. С. Исследование серологического опухолевого маркера Tu M2‑PK у больных раком почки. Российский онкологический журнал. 2005; 3: 30–32.Marshutina N. V., Sergeeva N. S. Serologicheskie opukholevye markery v pervichnoi diagnostike i monitoringe bol'nykh rakom molochnoi zhelezy. Rossiiskii onkologicheskii zhurnal. 2002; 4: 45–48. (Russian).Eigenbrodt E., Reinacher M., Scheefers-Borchel U., Scheefers H., Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells (review). In: Critical Reviews in Oncogenesis, CRC-Press, Boca Raton, Florida. (M. Perucho, ed.). 1992; 3 (1, 2): 91–115.Marshutina N. V., Sergeeva N. S. Serologicheskie opukholevye markery v pervichnoi diagnostike i monitoringe bol'nykh rakom molochnoi zhelezy. Rossiiskii onkologicheskii zhurnal. 2002; 4: 45–48. (Russian).He Q., Zhang J., Zou S., Li H., Wang X., Zhou S., Fornander T., Skog S. Concentration of tymidine kinase 1 (S‑TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep. 2005; 14 (4): 1013–1019.Sergeeva N. S., Rusakov I. G., Marshutina N. V., Rodina I. A., Akhmedova I. It., Kirsanova V. A., Makhmurova N. Т., Sergeeva V. S. Examination of a serological tumor marker Tu M2‑PK in patients with renal carcinoma. Rossiiskii onkologicheskii zhurnal. 2005; 3: 30–32. (Russian).Hardardottir H., Parmley T. H., Quirk J. G. Jr., Sanders M. M., Miller F. C., O'Brien T. J. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am. J. Obstet. Gynecol. 1990; 163 (6. Pt 1):1925–1931.Sergeeva N. S., Rusakov I. G., Marshutina N. V., Rodina I. A., Akhmedova I. It., Kirsanova V. A., Makhmurova N. Т., Sergeeva V. S. Examination of a serological tumor marker Tu M2‑PK in patients with renal carcinoma. Rossiiskii onkologicheskii zhurnal. 2005; 3: 30–32. (Russian).Gipson I. K., Blalock T., Tisdale A., Spurr-Michaud S., Allcorn S., Stavreus-Evers A., Gemzell K. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Bio Reprod. 2008; 78 (1): 134–142.Eigenbrodt E., Reinacher M., Scheefers-Borchel U., Scheefers H., Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells (review). In: Critical Reviews in Oncogenesis, CRC-Press, Boca Raton, Florida. (M. Perucho, ed.). 1992; 3 (1, 2): 91–115.Gubbels J. A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., Bera T. K., Connor J., Sathyanarayana B. K., Lee B., Pastan I., Patankar M. S. Mesothelin-MUC16 binding is a high affinity, N‑glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5 (1): 50.Eigenbrodt E., Reinacher M., Scheefers-Borchel U., Scheefers H., Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells (review). In: Critical Reviews in Oncogenesis, CRC-Press, Boca Raton, Florida. (M. Perucho, ed.). 1992; 3 (1, 2): 91–115.Gubbels J. A., Felder M., Horibata S., Belisle J. A., Kapur A., Holden H., Petrie S., Migneault M., Rancourt C., Connor J. P., Patankar M. S. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer. 2010. 20; 9: 11.He Q., Zhang J., Zou S., Li H., Wang X., Zhou S., Fornander T., Skog S. Concentration of tymidine kinase 1 (S‑TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep. 2005; 14 (4): 1013–1019.Nguyen H. N., Jacobson A., Patino–Paul R. New reference levels for CA125 in pre-and postmenopau-sal women. Prim Care Update Ob Gyns. 1998; 5 (4):157.He Q., Zhang J., Zou S., Li H., Wang X., Zhou S., Fornander T., Skog S. Concentration of tymidine kinase 1 (S‑TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep. 2005; 14 (4): 1013–1019.Sturgeon C. M., Duffy M. J., Stenman U. H. et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008; 54 (12): 11–79.Hardardottir H., Parmley T. H., Quirk J. G. Jr., Sanders M. M., Miller F. C., O'Brien T. J. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am. J. Obstet. Gynecol. 1990; 163 (6. Pt 1):1925–1931.Jacobs I., Bast R. C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4 (1): 1–12.Hardardottir H., Parmley T. H., Quirk J. G. Jr., Sanders M. M., Miller F. C., O'Brien T. J. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am. J. Obstet. Gynecol. 1990; 163 (6. Pt 1):1925–1931.Tuxen M. K. Tumor marker CA125 in ovarian cancer. J Tumor Marker Oncol. 2001; 16 (1): 49–67.Gipson I. K., Blalock T., Tisdale A., Spurr-Michaud S., Allcorn S., Stavreus-Evers A., Gemzell K. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Bio Reprod. 2008; 78 (1): 134–142.Kobayashi E., Ueda Y., Matsuzaki S., Yokoyama T., Kimura T., Yoshino K., Fujita M., Kimura T., Enomoto T. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21 (11): 1902–1912.Gipson I. K., Blalock T., Tisdale A., Spurr-Michaud S., Allcorn S., Stavreus-Evers A., Gemzell K. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Bio Reprod. 2008; 78 (1): 134–142.Ахмедова С. А. Совершенствование клинико-лабораторной концепции использования СА 125 у больных раком яичников: Дис. … канд. биол. наук: 14.00.14. Москва, 2003.Gubbels J. A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., Bera T. K., Connor J., Sathyanarayana B. K., Lee B., Pastan I., Patankar M. S. Mesothelin-MUC16 binding is a high affinity, N‑glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5 (1): 50.Topalak O., Saygili U., Soyturk M., Karaca N., Batur Y., Uslu T., Erten O. Serum, pleural effusion, and ascites CA‑125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol. 2002; 85 (1):108–113.Gubbels J. A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., Bera T. K., Connor J., Sathyanarayana B. K., Lee B., Pastan I., Patankar M. S. Mesothelin-MUC16 binding is a high affinity, N‑glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5 (1): 50.Sölétormos G., Duffy M. J., Othman Abu Hassan S., Verheijen R. H., Tholander B., Bast R. C. Jr., Gaarenstroom K. N., Sturgeon C. M., Bonfrer J. M., Petersen P. H., Troonen H., Carlo- Torre G., Kanty Kulpa J., Tuxen M. K., Molina R. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers (EGTM). Int J Gynecol Cancer. 2016; 26 (1): 43–51.Gubbels J. A., Felder M., Horibata S., Belisle J. A., Kapur A., Holden H., Petrie S., Migneault M., Rancourt C., Connor J. P., Patankar M. S. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer. 2010. 20; 9: 11.Nagele F., Petru E., Medl M., Kainz C., Graf A. H., Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995; 86 (2): 259–264.Gubbels J. A., Felder M., Horibata S., Belisle J. A., Kapur A., Holden H., Petrie S., Migneault M., Rancourt C., Connor J. P., Patankar M. S. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer. 2010. 20; 9: 11.Корнеева И. А., Новикова Е. Г., Сергеева Н. С. Современный взгляд на маркерный рецидив рака яичников. Российский онкологический журнал. 2010; 2: 54–7.Nguyen H. N., Jacobson A., Patino–Paul R. New reference levels for CA125 in pre-and postmenopau-sal women. Prim Care Update Ob Gyns. 1998; 5 (4):157.Riedinger J. M., Bonnetain F., Basuyau J. P., Eche N., Larbre H., Dalifard I., Wafflart J., Ricolleau G., Pichon M. F. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann Oncol. 2007; 18 (5): 881–885.Nguyen H. N., Jacobson A., Patino–Paul R. New reference levels for CA125 in pre-and postmenopau-sal women. Prim Care Update Ob Gyns. 1998; 5 (4):157.Liu P. Y., Alberts D. S., Monk B. J., Brady M., Moon J., Markman M. An early signal of CA‑125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25 (24): 3615–3620.Sturgeon C. M., Duffy M. J., Stenman U. H. et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008; 54 (12): 11–79.Aebi S., Castiglione M; ESMO Guidelines Working Group. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 4: 21–23.Sturgeon C. M., Duffy M. J., Stenman U. H. et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008; 54 (12): 11–79.Guppy A. E., Rustin G. J. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist. 2002; 7 (5): 437–443.Jacobs I., Bast R. C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4 (1): 1–12.Riedinger J. M., Bonnetain F., Basuyau J. P., Eche N., Larbre H., Dalifard I., Wafflart J., Ricolleau G., Pichon MF. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann. Oncol. 2007; 18 (5): 881–885.Jacobs I., Bast R. C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4 (1): 1–12.Сергеева Н. С., Маршутина Н. В., Алентов И. И., Корнеева И. А., Новикова Е. Г. Серологические опухолеассоциированные маркеры СА 125 и НЕ4 у больных раком яичников. Вопросы онкологии. 2013; 59 (2): 12–21.Tuxen M. K. Tumor marker CA125 in ovarian cancer. J Tumor Marker Oncol. 2001; 16 (1): 49–67.Хохлова С. В. Индивидуализация лечения больных раком яичников: Автореф. дисс. … докт. мед. наук: 14.01.12/ФГБНУ «РОНЦ им. Н. Н. Блохина». Москва, 2015.Tuxen M. K. Tumor marker CA125 in ovarian cancer. J Tumor Marker Oncol. 2001; 16 (1): 49–67.Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45 (2): 350–357.Kobayashi E., Ueda Y., Matsuzaki S., Yokoyama T., Kimura T., Yoshino K., Fujita M., Kimura T., Enomoto T. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21 (11): 1902–1912.Galgano M. T., Hampton G. M., Frierson H. F. Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19 (6): 847–853.Kobayashi E., Ueda Y., Matsuzaki S., Yokoyama T., Kimura T., Yoshino K., Fujita M., Kimura T., Enomoto T. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21 (11): 1902–1912.Bolstad N., Øijordsbakken M., Nustad K., Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012; 33 (1): 141–148.Akhmedova S. A. Sovershenstvovanie kliniko-laboratornoi kontseptsii ispol'zovaniya SA 125 u bol'nykh rakom yaichnikov: Dis. … kand. biol. nauk: 14.00.14. Mosсow, 2003. (Russian).Escudero J. M., Auge J. M., Filella X., Torne A., Pahisa J., Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011; 57 (11): 1534–1544.Akhmedova S. A. Sovershenstvovanie kliniko-laboratornoi kontseptsii ispol'zovaniya SA 125 u bol'nykh rakom yaichnikov: Dis. … kand. biol. nauk: 14.00.14. Mosсow, 2003. (Russian).Molina R., Escudero J. M., Augé J. M., Filella X., Foj L., Torné A., Lejarcegui J., Pahisa J. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011; 32 (6): 1087–1095.Topalak O., Saygili U., Soyturk M., Karaca N., Batur Y., Uslu T., Erten O. Serum, pleural effusion, and ascites CA‑125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol. 2002; 85 (1):108–113.Hertlein L., Stieber P., Kirschenhofer A., Krocker K., Nagel D., Lenhard M., Burges A. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012; 50 (12): 2181–2188.Topalak O., Saygili U., Soyturk M., Karaca N., Batur Y., Uslu T., Erten O. Serum, pleural effusion, and ascites CA‑125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol. 2002; 85 (1):108–113.Macedo A. C., da Rosa M. I., Lumertz S., Medeiros L. R. Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis. Int J Gynecol Cancer. 2014; 24 (7): 1222–1231.Sölétormos G., Duffy M. J., Othman Abu Hassan S., Verheijen R. H., Tholander B., Bast R. C. Jr., Gaarenstroom K. N., Sturgeon C. M., Bonfrer J. M., Petersen P. H., Troonen H., Carlo-Torre G., Kanty Kulpa J., Tuxen M. K., Molina R. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers (EGTM). Int J Gynecol Cancer. 2016; 26 (1): 43–51.Moore R. G., Brown A. K., Miller M. C., Skates S., Allard W. J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C. O., Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2007; 108 (2): 402–408.Sölétormos G., Duffy M. J., Othman Abu Hassan S., Verheijen R. H., Tholander B., Bast R. C. Jr., Gaarenstroom K. N., Sturgeon C. M., Bonfrer J. M., Petersen P. H., Troonen H., Carlo-Torre G., Kanty Kulpa J., Tuxen M. K., Molina R. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers (EGTM). Int J Gynecol Cancer. 2016; 26 (1): 43–51.Anastasi E., Marchei G. G., Viggiani V., Gennarini G., Frati L., Reale M. G. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010; 31 (2): 113–119.Nagele F., Petru E., Medl M., Kainz C., Graf A. H., Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995; 86 (2): 259–264.Сергеева Н. С., Алентов И. И., Маршутина Н. В., Корнеева И. А., Новикова Е. Г. Белок эпидидимиса HE4 как дополнительный серологический маркер для мониторинга больных раком яичников. Онкология. Журнал им. П. А. Герцена. 2014; 2 (2): 14–20.Nagele F., Petru E., Medl M., Kainz C., Graf A. H., Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995; 86 (2): 259–264.Moore R. G., McMeekin D. S., Brown A. K., DiSilvestro P., Miller M. C., Allard W. J., Gajewski W., Kurman R., Bast R. C. Jr, Skates S. J. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009; 112 (1): 40–46.Korneyeva I. A., Novikova Ye. G., Sergeyeva N. S. Present views of the marker recurrence of ovarian cancer. Rossiiskii onkologicheskii zhurnal. 2010; 2: 54–7. (Russian).Li J., Chen H., Mariani A., Chen D., Klatt E., Podratz K., Drapkin R., Broaddus R., Dowdy S., Jiang S. W. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci. 2013; 15; 14 (3): 6026–6043.Korneyeva I. A., Novikova Ye. G., Sergeyeva N. S. Present views of the marker recurrence of ovarian cancer. Rossiiskii onkologicheskii zhurnal. 2010; 2: 54–7. (Russian).Ortiz-Muñoz B., Aznar-Oroval E., García García A., Covisa Peris A., Perez Ballestero P., Sanchez Yepes M., Garcia Lozano T., Illueca Ballester C., García Garcia E. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol. 2014; 35 (7): 7249–7258.Riedinger J. M., Bonnetain F., Basuyau J. P., Eche N., Larbre H., Dalifard I., Wafflart J., Ricolleau G., Pichon M. F. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann Oncol. 2007; 18 (5): 881–885.Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M., Salvagno G. L., Franchi M., Lippi G., Guidi GC. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011; 49 (3): 521–525.Riedinger J. M., Bonnetain F., Basuyau J. P., Eche N., Larbre H., Dalifard I., Wafflart J., Ricolleau G., Pichon M. F. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann Oncol. 2007; 18 (5): 881–885.Partheen K., Kristjansdottir B., Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA‑125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011; 22 (4): 244–252.Liu P. Y., Alberts D. S., Monk B. J., Brady M., Moon J., Markman M. An early signal of CA‑125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25 (24): 3615–3620.Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lowe D. G., Oram D. H. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353 (9160): 1207–1210.Liu P. Y., Alberts D. S., Monk B. J., Brady M., Moon J., Markman M. An early signal of CA‑125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25 (24): 3615–3620.Jellum E., Andersen A., Lund-Larsen P., Theodorsen L., Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect. 1995; 103 Suppl 3: 85–88.Aebi S., Castiglione M; ESMO Guidelines Working Group. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 4: 21–23.Сергеева Н. С., Маршутина Н. В. Опухолеассоциированные маркеры в скрининговых программах, направленных на активное выявление рака яичников: реальность, проблемы и перспективы. Практическая онкология. 2010; 11 (2): 110– 119.Aebi S., Castiglione M; ESMO Guidelines Working Group. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 4: 21–23.Wang M. C., Valenzuela L. A., Murphy G. P., Chu T. M. Purification of a human prostate specific antigen Invest Urol. 1979; 17 (2): 159–163.Guppy A. E., Rustin G. J. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist. 2002; 7 (5): 437–443.Ban Y., Wang M. C., Watt K. W., Loor R., Chu T. M. The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun. 1984; 123 (2): 482–488.Guppy A. E., Rustin G. J. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist. 2002; 7 (5): 437–443.Balk S. P., Ko Y. J., Bubley G. J. Biology of prostate-specific antigen. J Clin Oncol. 2003; 21 (2): 383–391.Riedinger J. M., Bonnetain F., Basuyau J. P., Eche N., Larbre H., Dalifard I., Wafflart J., Ricolleau G., Pichon MF. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann. Oncol. 2007; 18 (5): 881–885.Bindukumar B., Schwartz S. A., Nair M. P., Aalinkeel R., Kawinski E., Chadha K. C. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005; 7 (3): 241–252.Riedinger J. M., Bonnetain F., Basuyau J. P., Eche N., Larbre H., Dalifard I., Wafflart J., Ricolleau G., Pichon MF. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome. Ann. Oncol. 2007; 18 (5): 881–885.Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–763.Sergeeva N. S., Marshutina N. V., Alentov I. I., Korneeva I. A., Novikova E. G. Serum tumor markers СА125 and НЕ4 in ovary cancer patients. Voprosy oncologii. 2013; 59 (2): 12–21. (Russian).Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T., Lange P. H., Subong E. N., Parson R. E., Gasior G. H., Loveland K. G., Southwick P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279 (19): 1542–1547.Sergeeva N. S., Marshutina N. V., Alentov I. I., Korneeva I. A., Novikova E. G. Serum tumor markers СА125 and НЕ4 in ovary cancer patients. Voprosy oncologii. 2013; 59 (2): 12–21. (Russian).Heidenreich A., Bolla M., Joniau S. et al. European Associated of Urology. Guidelines — 2010. (Перевод: Антонова О. В., научное редактирование: Алексеев Б. Я., Нюшко К. М. «Рекомендации по лечению рака предстательной железы» Европейской ассоциации урологов, версия 2010 г.).Khokhlova S. V. Individualizatsiya lecheniya bol'nykh rakom yaichnikov: Avtoref. diss. … dokt. med. nauk: 14.01.12/FGBNU «RONTs im. N. N. Blokhina». Moscow, 2015. (Russian).Сергеева Н. С., Маршутина Н. В., Солохина М. П., Алентов И. И., Парилова Н. К., Зенкина Е. В., Скачкова Т. Е. Современные представления о серологических опухолеассоциированных маркерах и их месте в онкологии. Успехи молекулярной онкологии. 2014; 1: 69–81.Khokhlova S. V. Individualizatsiya lecheniya bol'nykh rakom yaichnikov: Avtoref. diss. … dokt. med. nauk: 14.01.12/FGBNU «RONTs im. N. N. Blokhina». Moscow, 2015. (Russian).Mikolajczyk S. D., Marker K. M., Millar L. S., Kumar A., Saedi M. S., Payne J. K., Evans C. L., Gasior C. L., Linton H. J., Carpenter P., Rittenhouse H. G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 15; 61 (18): 6958–6963.Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45 (2):350–357.Mikolajczyk S. D., Catalona W. J., Evans C. L., Linton H. J. Millar L. S., Marker K. M., Katir D., Amirkhan A., Rittenhouse H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004; 50 (6): 1017–1025.Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45 (2):350–357.Sokoll L. J., Wang Y., Feng Z., Kagan J., Partin A. W., Sanda M. G., Thompson I. M., Chan D. W. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol. 2008; 180 (2): 539–543.Galgano M. T., Hampton G. M., Frierson H. F. Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19 (6): 847–853.Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., van Schaik R. H., Mizrahi I. A. A Multi-Center Study of [–2]Pro-prostate- specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185 (5): 1650–1655.Galgano M. T., Hampton G. M., Frierson H. F. Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19 (6): 847–853.Lazzeri M., Haese A., Taille A., Palou Redorta J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le Corvoisier P., Alberola Bou J., Esquena Fernández S., Graefen M., Guazzoni G. Serum Isoform [S2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol. 2013; 63 (6): 986–994.Bolstad N., Øijordsbakken M., Nustad K., Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012; 33 (1): 141–148.Heidegger I., Klocker H., Steiner E., Skradski V., Ladurner M., Pichler R., Schäfer G., Horninger W., Bektic J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2014 Mar;17 (1):70–4Bolstad N., Øijordsbakken M., Nustad K., Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012; 33 (1): 141–148.Чиссов В. И., Дарьялова С. Л. (Ред.): Руководство по онкологии. М.: «Медицинское информационное агентство», 2008.Escudero J. M., Auge J. M., Filella X., Torne A., Pahisa J., Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011; 57 (11): 1534–1544.Schrőder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A.; ERSPC Investigators. Screening and prostate — cancer mortality in a randomized. European study. N Engl. J Med. 2009; 360: 1320–1328.Escudero J. M., Auge J. M., Filella X., Torne A., Pahisa J., Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011; 57 (11): 1534–1544.Fraser C. G., Matthew C. M., Mowat N. A., Wilson J. A., Carey F. A., Steele R. J. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study. Lancet Oncol. 2006; 7 (2): 127–131.Molina R., Escudero J. M., Augé J. M., Filella X., Foj L., Torné A., Lejarcegui J., Pahisa J. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011; 32 (6): 1087–1095.Zauber A. G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications o f Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.Molina R., Escudero J. M., Augé J. M., Filella X., Foj L., Torné A., Lejarcegui J., Pahisa J. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011; 32 (6): 1087–1095.Benson V. S., Patnick J., Davies A. K. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357–1367.Hertlein L., Stieber P., Kirschenhofer A., Krocker K., Nagel D., Lenhard M., Burges A. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012; 50 (12): 2181–2188.Hol L., de Jonge V., van Leerdam M. E., van Ballegooijen M., Looman C. W., van Vuuren A. J., Reijerink J. C., Habbema J. D., Essink-Bot M. L., Kuipers E. J. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010; 46 (11): 2059–2066.Hertlein L., Stieber P., Kirschenhofer A., Krocker K., Nagel D., Lenhard M., Burges A. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012; 50 (12): 2181–2188.Hol L., Kuipers E. J., van Ballegooijen M., van Vuuren A. J., Reijerink J. C., Habbema D. J., van Leerdam M. E. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer. 2012; 130 (9): 2096–2102.Macedo A. C., da Rosa M. I., Lumertz S., Medeiros L. R. Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis. Int J Gynecol Cancer. 2014; 24 (7): 1222–1231.Scholefield J. H., Moss S., Sufi F., Mangham C. M., Hardcastle J. D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002; 50 (6): 840–844.Macedo A. C., da Rosa M. I., Lumertz S., Medeiros L. R. Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis. Int J Gynecol Cancer. 2014; 24 (7): 1222–1231.European Colorectal Cancer Screening Guidelines Working Group, von Karsa L. J., Patnick N., Segnan W., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. Overview: European guidelines for quality assurance in CRC screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1): 51–59.Moore R. G., Brown A. K., Miller M. C., Skates S., Allard W. J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C. O., Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2007; 108 (2): 402–408.Vilkin A., Rozen P., Levi Z., Waked A., Maoz E., Birkenfeld S., Niv Y. Performance characteristics and evaluation of an automated- developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100 (11): 2519–2525.Moore R. G., Brown A. K., Miller M. C., Skates S., Allard W. J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C. O., Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2007; 108 (2): 402–408.Чиссов В. И., Сергеева Н. С., Зенкина Е. В., Маршутина Н. В. Эволюция копро-тестов в активном выявлении колоректального рака. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2012; 22 (6): 44–52.Anastasi E., Marchei G. G., Viggiani V., Gennarini G., Frati L., Reale M. G. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010; 31 (2): 113–119.Decker K. M., Demers A. A., Nugent Z., iswanger N., Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. Am. J. Gastroenterol. 2015; 110 (12):1640–1646.Anastasi E., Marchei G. G., Viggiani V., Gennarini G., Frati L., Reale M. G. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010; 31 (2): 113–119.Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95 (12): 6870–6875.Sergeeva N. S., Alentov I. I., Marshutina N. V., Korneeva I. A., Novikova E. G. Epididymis protein 4 as an additional serological marker for monitoring patients with ovarian cancer. Onkologiia. Zhurnal imeni P. A. Gerzena. 2014; 2 (2): 14–20. (Russian).Минимальные клинические рекомендации Европейского Общества Медицинской Онкологии (ЕSМО). Редакторы русского перевода: С. А. Тюляндин, Д. А. Носов, Н. И. Переводчикова. М.: Издательская группа РОНЦ им. Н. Н. Блохина РАМН, 2010.Sergeeva N. S., Alentov I. I., Marshutina N. V., Korneeva I. A., Novikova E. G. Epididymis protein 4 as an additional serological marker for monitoring patients with ovarian cancer. Onkologiia. Zhurnal imeni P. A. Gerzena. 2014; 2 (2): 14–20. (Russian).Christie M., Jorissen R. N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I. T., Mc-Laughlin S., Ward R. L., Hawkins N. J., Ruszkiewicz A. R., Moore J., Burgess A. W., Busam D., Zhao Q., Strausberg R. L., Simpson A. J., Tomlinson I. P., Gibbs P., Sieber O. M. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013; 32 (39): 4675–4682.Moore R. G., McMeekin D. S., Brown A. K., DiSilvestro P., Miller M. C., Allard W. J., Gajewski W., Kurman R., Bast R. C. Jr, Skates S. J. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009; 112 (1): 40–46.Егоренков В. В., Моисеенко Ф. В. Скрининг рака толстой кишки. Практическая онкология. 2010; 11 (2): 81–87.Moore R. G., McMeekin D. S., Brown A. K., DiSilvestro P., Miller M. C., Allard W. J., Gajewski W., Kurman R., Bast R. C. Jr, Skates S. J. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009; 112 (1): 40–46.Robertson C., Church S. W., Nagar H. A., Price J., Hall P. A., Russell S. E. Properties of Septin9 isoforms and the requirement for GTP binding. J Pathol. 2004; 203 (1): 519–527.Li J., Chen H., Mariani A., Chen D., Klatt E., Podratz K., Drapkin R., Broaddus R., Dowdy S., Jiang S. W. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci. 2013; 15; 14 (3): 6026–6043.De Vos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K. V., Grützmann R., Pilarsky C., Habermann J. K., Fleshner P. R., Oubre B. M., Day R., Sledziewski A. Z., Lofton- Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 2009; 55 (7): 1337–1346.Li J., Chen H., Mariani A., Chen D., Klatt E., Podratz K., Drapkin R., Broaddus R., Dowdy S., Jiang S. W. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci. 2013; 15; 14 (3): 6026–6043.Heichman K. A., Warren J. D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med. 2012; 50 (10): 1707–1721.Ortiz-Muñoz B., Aznar-Oroval E., García García A., Covisa Peris A., Perez Ballestero P., Sanchez Yepes M., Garcia Lozano T., Illueca Ballester C., García Garcia E. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol. 2014; 35 (7): 7249–7258.Ortiz-Muñoz B., Aznar-Oroval E., García García A., Covisa Peris A., Perez Ballestero P., Sanchez Yepes M., Garcia Lozano T., Illueca Ballester C., García Garcia E. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol. 2014; 35 (7): 7249–7258.Ortiz-Muñoz B., Aznar-Oroval E., García García A., Covisa Peris A., Perez Ballestero P., Sanchez Yepes M., Garcia Lozano T., Illueca Ballester C., García Garcia E. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol. 2014; 35 (7): 7249–7258.Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M., Salvagno G. L., Franchi M., Lippi G., Guidi GC. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011; 49 (3): 521–525.Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M., Salvagno G. L., Franchi M., Lippi G., Guidi GC. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011; 49 (3): 521–525.Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M., Salvagno G. L., Franchi M., Lippi G., Guidi GC. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011; 49 (3): 521–525.Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M., Salvagno G. L., Franchi M., Lippi G., Guidi GC. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011; 49 (3): 521–525.Partheen K., Kristjansdottir B., Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA‑125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011; 22 (4): 244–252.Partheen K., Kristjansdottir B., Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA‑125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011; 22 (4): 244–252.Partheen K., Kristjansdottir B., Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA‑125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011; 22 (4): 244–252.Partheen K., Kristjansdottir B., Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA‑125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011; 22 (4): 244–252.Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lowe D. G., Oram D. H. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353 (9160): 1207–1210.Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lowe D. G., Oram D. H. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353 (9160): 1207–1210.Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lowe D. G., Oram D. H. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353 (9160): 1207–1210.Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lowe D. G., Oram D. H. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353 (9160): 1207–1210.Jellum E., Andersen A., Lund-Larsen P., Theodorsen L., Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect. 1995; 103 Suppl 3: 85–88.Jellum E., Andersen A., Lund-Larsen P., Theodorsen L., Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect. 1995; 103 Suppl 3: 85–88.Jellum E., Andersen A., Lund-Larsen P., Theodorsen L., Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect. 1995; 103 Suppl 3: 85–88.Jellum E., Andersen A., Lund-Larsen P., Theodorsen L., Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect. 1995; 103 Suppl 3: 85–88.Sergeeva N. S., Marshutina N. V. Opukholeassotsiirovannye markery v skriningovykh programmakh, napravlennykh na aktivnoe vyyavlenie raka yaichnikov: real'nost', problemy i perspektivy. Prakticheskaya onkologiya. 2010; 11 (2): 110–119. (Russian).Sergeeva N. S., Marshutina N. V. Opukholeassotsiirovannye markery v skriningovykh programmakh, napravlennykh na aktivnoe vyyavlenie raka yaichnikov: real'nost', problemy i perspektivy. Prakticheskaya onkologiya. 2010; 11 (2): 110–119. (Russian).Sergeeva N. S., Marshutina N. V. Opukholeassotsiirovannye markery v skriningovykh programmakh, napravlennykh na aktivnoe vyyavlenie raka yaichnikov: real'nost', problemy i perspektivy. Prakticheskaya onkologiya. 2010; 11 (2): 110–119. (Russian).Sergeeva N. S., Marshutina N. V. Opukholeassotsiirovannye markery v skriningovykh programmakh, napravlennykh na aktivnoe vyyavlenie raka yaichnikov: real'nost', problemy i perspektivy. Prakticheskaya onkologiya. 2010; 11 (2): 110–119. (Russian).Wang M. C., Valenzuela L. A., Murphy G. P., Chu T. M. Purification of a human prostate specific antigen Invest Urol. 1979; 17 (2): 159–163.Wang M. C., Valenzuela L. A., Murphy G. P., Chu T. M. Purification of a human prostate specific antigen Invest Urol. 1979; 17 (2): 159–163.Wang M. C., Valenzuela L. A., Murphy G. P., Chu T. M. Purification of a human prostate specific antigen Invest Urol. 1979; 17 (2): 159–163.Wang M. C., Valenzuela L. A., Murphy G. P., Chu T. M. Purification of a human prostate specific antigen Invest Urol. 1979; 17 (2): 159–163.Ban Y., Wang M. C., Watt K. W., Loor R., Chu T. M. The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun. 1984; 123 (2): 482–488.Ban Y., Wang M. C., Watt K. W., Loor R., Chu T. M. The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun. 1984; 123 (2): 482–488.Ban Y., Wang M. C., Watt K. W., Loor R., Chu T. M. The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun. 1984; 123 (2): 482–488.Ban Y., Wang M. C., Watt K. W., Loor R., Chu T. M. The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun. 1984; 123 (2): 482–488.Balk S. P., Ko Y. J., Bubley G. J. Biology of prostate-specific antigen. J Clin Oncol. 2003; 21 (2): 383–391.Balk S. P., Ko Y. J., Bubley G. J. Biology of prostate-specific antigen. J Clin Oncol. 2003; 21 (2): 383–391.Balk S. P., Ko Y. J., Bubley G. J. Biology of prostate-specific antigen. J Clin Oncol. 2003; 21 (2): 383–391.Balk S. P., Ko Y. J., Bubley G. J. Biology of prostate-specific antigen. J Clin Oncol. 2003; 21 (2): 383–391.Bindukumar B., Schwartz S. A., Nair M. P., Aalinkeel R., Kawinski E., Chadha K. C. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005; 7 (3): 241–252.Bindukumar B., Schwartz S. A., Nair M. P., Aalinkeel R., Kawinski E., Chadha K. C. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005; 7 (3): 241–252.Bindukumar B., Schwartz S. A., Nair M. P., Aalinkeel R., Kawinski E., Chadha K. C. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005; 7 (3): 241–252.Bindukumar B., Schwartz S. A., Nair M. P., Aalinkeel R., Kawinski E., Chadha K. C. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005; 7 (3): 241–252.Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate- specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–763.Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate- specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–763.Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate- specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–763.Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate- specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–763.Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate- specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–763.Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate- specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–763.Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T., Lange P. H., Subong E. N., Parson R. E., Gasior G. H., Loveland K. G., Southwick P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279 (19): 1542–1547.Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T., Lange P. H., Subong E. N., Parson R. E., Gasior G. H., Loveland K. G., Southwick P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279 (19): 1542–1547.Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T., Lange P. H., Subong E. N., Parson R. E., Gasior G. H., Loveland K. G., Southwick P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279 (19): 1542–1547.Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T., Lange P. H., Subong E. N., Parson R. E., Gasior G. H., Loveland K. G., Southwick P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279 (19): 1542–1547.Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T., Lange P. H., Subong E. N., Parson R. E., Gasior G. H., Loveland K. G., Southwick P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279 (19): 1542–1547.Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T., Lange P. H., Subong E. N., Parson R. E., Gasior G. H., Loveland K. G., Southwick P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279 (19): 1542–1547.Heidenreich A., Bolla M., Joniau S. et al. European Associated of Urology. Guidelines — 2010. (Perevod: Antonova O. V., nauchnoe redaktirovanie: Alekseev B.Ya., Nyushko K. M. «Rekomendatsii po lecheniyu raka predstatel'noi zhelezy» Evropeiskoi assotsiatsii urologov, versiya 2010 g.). (Russian).Heidenreich A., Bolla M., Joniau S. et al. European Associated of Urology. Guidelines — 2010. (Perevod: Antonova O. V., nauchnoe redaktirovanie: Alekseev B.Ya., Nyushko K. M. «Rekomendatsii po lecheniyu raka predstatel'noi zhelezy» Evropeiskoi assotsiatsii urologov, versiya 2010 g.). (Russian).Heidenreich A., Bolla M., Joniau S. et al. European Associated of Urology. Guidelines — 2010. (Perevod: Antonova O. V., nauchnoe redaktirovanie: Alekseev B.Ya., Nyushko K. M. «Rekomendatsii po lecheniyu raka predstatel'noi zhelezy» Evropeiskoi assotsiatsii urologov, versiya 2010 g.). (Russian).Heidenreich A., Bolla M., Joniau S. et al. European Associated of Urology. Guidelines — 2010. (Perevod: Antonova O. V., nauchnoe redaktirovanie: Alekseev B.Ya., Nyushko K. M. «Rekomendatsii po lecheniyu raka predstatel'noi zhelezy» Evropeiskoi assotsiatsii urologov, versiya 2010 g.). (Russian).Heidenreich A., Bolla M., Joniau S. et al. European Associated of Urology. Guidelines — 2010. (Perevod: Antonova O. V., nauchnoe redaktirovanie: Alekseev B.Ya., Nyushko K. M. «Rekomendatsii po lecheniyu raka predstatel'noi zhelezy» Evropeiskoi assotsiatsii urologov, versiya 2010 g.). (Russian).Heidenreich A., Bolla M., Joniau S. et al. European Associated of Urology. Guidelines — 2010. (Perevod: Antonova O. V., nauchnoe redaktirovanie: Alekseev B.Ya., Nyushko K. M. «Rekomendatsii po lecheniyu raka predstatel'noi zhelezy» Evropeiskoi assotsiatsii urologov, versiya 2010 g.). (Russian).Sergeeva N. S., Marshutina N. V., Solokhina M. P., Alentov I. I., Parilova N. K., Zenkina E. V., Skatchkova T. E. Modern conceptions of serological tumor markers and their role in oncology. Advances in molecular oncology. 2014; 1: 69–81. (Russian).Sergeeva N. S., Marshutina N. V., Solokhina M. P., Alentov I. I., Parilova N. K., Zenkina E. V., Skatchkova T. E. Modern conceptions of serological tumor markers and their role in oncology. Advances in molecular oncology. 2014; 1: 69–81. (Russian).Sergeeva N. S., Marshutina N. V., Solokhina M. P., Alentov I. I., Parilova N. K., Zenkina E. V., Skatchkova T. E. Modern conceptions of serological tumor markers and their role in oncology. Advances in molecular oncology. 2014; 1: 69–81. (Russian).Sergeeva N. S., Marshutina N. V., Solokhina M. P., Alentov I. I., Parilova N. K., Zenkina E. V., Skatchkova T. E. Modern conceptions of serological tumor markers and their role in oncology. Advances in molecular oncology. 2014; 1: 69–81. (Russian).Sergeeva N. S., Marshutina N. V., Solokhina M. P., Alentov I. I., Parilova N. K., Zenkina E. V., Skatchkova T. E. Modern conceptions of serological tumor markers and their role in oncology. Advances in molecular oncology. 2014; 1: 69–81. (Russian).Sergeeva N. S., Marshutina N. V., Solokhina M. P., Alentov I. I., Parilova N. K., Zenkina E. V., Skatchkova T. E. Modern conceptions of serological tumor markers and their role in oncology. Advances in molecular oncology. 2014; 1: 69–81. (Russian).Mikolajczyk S. D., Marker K. M., Millar L. S., Kumar A., SaediM. S., Payne J. K., Evans C. L., Gasior C. L., Linton H. J., Carpenter P., Rittenhouse H. G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 15; 61 (18): 6958–6963.Mikolajczyk S. D., Marker K. M., Millar L. S., Kumar A., SaediM. S., Payne J. K., Evans C. L., Gasior C. L., Linton H. J., Carpenter P., Rittenhouse H. G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 15; 61 (18): 6958–6963.Mikolajczyk S. D., Marker K. M., Millar L. S., Kumar A., SaediM. S., Payne J. K., Evans C. L., Gasior C. L., Linton H. J., Carpenter P., Rittenhouse H. G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 15; 61 (18): 6958–6963.Mikolajczyk S. D., Marker K. M., Millar L. S., Kumar A., SaediM. S., Payne J. K., Evans C. L., Gasior C. L., Linton H. J., Carpenter P., Rittenhouse H. G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 15; 61 (18): 6958–6963.Mikolajczyk S. D., Marker K. M., Millar L. S., Kumar A., SaediM. S., Payne J. K., Evans C. L., Gasior C. L., Linton H. J., Carpenter P., Rittenhouse H. G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 15; 61 (18): 6958–6963.Mikolajczyk S. D., Marker K. M., Millar L. S., Kumar A., SaediM. S., Payne J. K., Evans C. L., Gasior C. L., Linton H. J., Carpenter P., Rittenhouse H. G. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001, 15; 61 (18): 6958–6963.Mikolajczyk S. D., Catalona W. J., Evans C. L., Linton H. J., Millar L. S., Marker K. M., Katir D., Amirkhan A., Rittenhouse H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;Mikolajczyk S. D., Catalona W. J., Evans C. L., Linton H. J., Millar L. S., Marker K. M., Katir D., Amirkhan A., Rittenhouse H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;Mikolajczyk S. D., Catalona W. J., Evans C. L., Linton H. J., Millar L. S., Marker K. M., Katir D., Amirkhan A., Rittenhouse H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;Mikolajczyk S. D., Catalona W. J., Evans C. L., Linton H. J., Millar L. S., Marker K. M., Katir D., Amirkhan A., Rittenhouse H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;Mikolajczyk S. D., Catalona W. J., Evans C. L., Linton H. J., Millar L. S., Marker K. M., Katir D., Amirkhan A., Rittenhouse H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;Mikolajczyk S. D., Catalona W. J., Evans C. L., Linton H. J., Millar L. S., Marker K. M., Katir D., Amirkhan A., Rittenhouse H. G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;50 (6): 1017–1025.50 (6): 1017–1025.50 (6): 1017–1025.50 (6): 1017–1025.50 (6): 1017–1025.50 (6): 1017–1025.Sokoll L. J., Wang Y., Feng Z., Kagan J., Partin A. W., Sanda M. G., Thompson I. M., Chan D. W. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol. 2008; 180 (2): 539–543.Sokoll L. J., Wang Y., Feng Z., Kagan J., Partin A. W., Sanda M. G., Thompson I. M., Chan D. W. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol. 2008; 180 (2): 539–543.Sokoll L. J., Wang Y., Feng Z., Kagan J., Partin A. W., Sanda M. G., Thompson I. M., Chan D. W. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol. 2008; 180 (2): 539–543.Sokoll L. J., Wang Y., Feng Z., Kagan J., Partin A. W., Sanda M. G., Thompson I. M., Chan D. W. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol. 2008; 180 (2): 539–543.Sokoll L. J., Wang Y., Feng Z., Kagan J., Partin A. W., Sanda M. G., Thompson I. M., Chan D. W. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol. 2008; 180 (2): 539–543.Sokoll L. J., Wang Y., Feng Z., Kagan J., Partin A. W., Sanda M. G., Thompson I. M., Chan D. W. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol. 2008; 180 (2): 539–543.Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., van Schaik R. H., Mizrahi I. A. A Multi-Center Study of [–2]Pro-prostate-specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185 (5): 1650–1655.Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., van Schaik R. H., Mizrahi I. A. A Multi-Center Study of [–2]Pro-prostate-specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185 (5): 1650–1655.Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., van Schaik R. H., Mizrahi I. A. A Multi-Center Study of [–2]Pro-prostate-specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185 (5): 1650–1655.Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., van Schaik R. H., Mizrahi I. A. A Multi-Center Study of [–2]Pro-prostate-specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185 (5): 1650–1655.Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., van Schaik R. H., Mizrahi I. A. A Multi-Center Study of [–2]Pro-prostate-specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185 (5): 1650–1655.Catalona W. J., Partin A. W., Sanda M. G., Wei J. T., Klee G. G., Bangma C. H., Slawin K. M., Marks L. S., Loeb S., Broyles D. L., Shin S. S., Cruz A. B., Chan D. W., Sokoll L. J., Roberts W. L., van Schaik R. H., Mizrahi I. A. A Multi-Center Study of [–2]Pro-prostate-specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol. 2011; 185 (5): 1650–1655.Lazzeri M., Haese A., Taille A., Palou Redorta J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le Corvoisier P., Alberola Bou J., Esquena Fernández S., Graefen M., Guazzoni G. Serum Isoform [S2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol. 2013; 63 (6): 986–994.Lazzeri M., Haese A., Taille A., Palou Redorta J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le Corvoisier P., Alberola Bou J., Esquena Fernández S., Graefen M., Guazzoni G. Serum Isoform [S2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol. 2013; 63 (6): 986–994.Lazzeri M., Haese A., Taille A., Palou Redorta J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le Corvoisier P., Alberola Bou J., Esquena Fernández S., Graefen M., Guazzoni G. Serum Isoform [S2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol. 2013; 63 (6): 986–994.Lazzeri M., Haese A., Taille A., Palou Redorta J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le Corvoisier P., Alberola Bou J., Esquena Fernández S., Graefen M., Guazzoni G. Serum Isoform [S2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol. 2013; 63 (6): 986–994.Lazzeri M., Haese A., Taille A., Palou Redorta J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le Corvoisier P., Alberola Bou J., Esquena Fernández S., Graefen M., Guazzoni G. Serum Isoform [S2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol. 2013; 63 (6): 986–994.Lazzeri M., Haese A., Taille A., Palou Redorta J., McNicholas T., Lughezzani G., Scattoni V., Bini V., Freschi M., Sussman A., Ghaleh B., Le Corvoisier P., Alberola Bou J., Esquena Fernández S., Graefen M., Guazzoni G. Serum Isoform [S2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol. 2013; 63 (6): 986–994.Heidegger I., Klocker H., Steiner E., Skradski V., Ladurner M., Pichler R., Schäfer G., Horninger W., Bektic J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2014 Mar;17 (1):70–4Heidegger I., Klocker H., Steiner E., Skradski V., Ladurner M., Pichler R., Schäfer G., Horninger W., Bektic J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2014 Mar;17 (1):70–4Heidegger I., Klocker H., Steiner E., Skradski V., Ladurner M., Pichler R., Schäfer G., Horninger W., Bektic J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2014 Mar;17 (1):70–4Heidegger I., Klocker H., Steiner E., Skradski V., Ladurner M., Pichler R., Schäfer G., Horninger W., Bektic J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2014 Mar;17 (1):70–4Heidegger I., Klocker H., Steiner E., Skradski V., Ladurner M., Pichler R., Schäfer G., Horninger W., Bektic J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2014 Mar;17 (1):70–4Heidegger I., Klocker H., Steiner E., Skradski V., Ladurner M., Pichler R., Schäfer G., Horninger W., Bektic J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis. 2014 Mar;17 (1):70–4Chissov V. I., Dar'yalova S. L. (eds.): Rukovodstvo po onkologii. Moscow: «Meditsinskoe informatsionnoe agentstvo» Publ., 2008. (Russian).Chissov V. I., Dar'yalova S. L. (eds.): Rukovodstvo po onkologii. Moscow: «Meditsinskoe informatsionnoe agentstvo» Publ., 2008. (Russian).Chissov V. I., Dar'yalova S. L. (eds.): Rukovodstvo po onkologii. Moscow: «Meditsinskoe informatsionnoe agentstvo» Publ., 2008. (Russian).Chissov V. I., Dar'yalova S. L. (eds.): Rukovodstvo po onkologii. Moscow: «Meditsinskoe informatsionnoe agentstvo» Publ., 2008. (Russian).Chissov V. I., Dar'yalova S. L. (eds.): Rukovodstvo po onkologii. Moscow: «Meditsinskoe informatsionnoe agentstvo» Publ., 2008. (Russian).Chissov V. I., Dar'yalova S. L. (eds.): Rukovodstvo po onkologii. Moscow: «Meditsinskoe informatsionnoe agentstvo» Publ., 2008. (Russian).Schrőder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A.; ERSPC Investigators. Screening and prostate — cancer mortality in a randomized. European study. N Engl J Med. 2009; 360: 1320–1328.Schrőder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A.; ERSPC Investigators. Screening and prostate — cancer mortality in a randomized. European study. N Engl J Med. 2009; 360: 1320–1328.Schrőder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A.; ERSPC Investigators. Screening and prostate — cancer mortality in a randomized. European study. N Engl J Med. 2009; 360: 1320–1328.Schrőder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A.; ERSPC Investigators. Screening and prostate — cancer mortality in a randomized. European study. N Engl J Med. 2009; 360: 1320–1328.Schrőder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A.; ERSPC Investigators. Screening and prostate — cancer mortality in a randomized. European study. N Engl J Med. 2009; 360: 1320–1328.Schrőder F. H., Hugosson J., Roobol M. J., Tammela T. L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A.; ERSPC Investigators. Screening and prostate — cancer mortality in a randomized. European study. N Engl J Med. 2009; 360: 1320–1328.Fraser C. G., Matthew C. M., Mowat N. A., Wilson J. A., Carey F. A., Steele R. J. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study. Lancet Oncol. 2006; 7 (2): 127–131.Fraser C. G., Matthew C. M., Mowat N. A., Wilson J. A., Carey F. A., Steele R. J. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study. Lancet Oncol. 2006; 7 (2): 127–131.Fraser C. G., Matthew C. M., Mowat N. A., Wilson J. A., Carey F. A., Steele R. J. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study. Lancet Oncol. 2006; 7 (2): 127–131.Fraser C. G., Matthew C. M., Mowat N. A., Wilson J. A., Carey F. A., Steele R. J. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study. Lancet Oncol. 2006; 7 (2): 127–131.Fraser C. G., Matthew C. M., Mowat N. A., Wilson J. A., Carey F. A., Steele R. J. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study. Lancet Oncol. 2006; 7 (2): 127–131.Fraser C. G., Matthew C. M., Mowat N. A., Wilson J. A., Carey F. A., Steele R. J. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study. Lancet Oncol. 2006; 7 (2): 127–131.Zauber A. G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.Zauber A. G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.Zauber A. G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.Zauber A. G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.Zauber A. G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.Zauber A. G. Adherence to Screening in a Randomized Controlled Trial of a one Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction. WEO Colorectal Cancer Screening Committee Meeting. 2012.Benson V. S., Patnick J., Davies A. K. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357–1367.Benson V. S., Patnick J., Davies A. K. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357–1367.Benson V. S., Patnick J., Davies A. K. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357–1367.Benson V. S., Patnick J., Davies A. K. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357–1367.Benson V. S., Patnick J., Davies A. K. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357–1367.Benson V. S., Patnick J., Davies A. K. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357–1367.Hol L., de Jonge V., van Leerdam M. E., van Ballegooijen M., Looman C. W., van Vuuren A. J., Reijerink J. C., Habbema J. D., Essink-Bot M. L., Kuipers E. J. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010; 46 (11): 2059–2066.Hol L., de Jonge V., van Leerdam M. E., van Ballegooijen M., Looman C. W., van Vuuren A. J., Reijerink J. C., Habbema J. D., Essink-Bot M. L., Kuipers E. J. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010; 46 (11): 2059–2066.Hol L., de Jonge V., van Leerdam M. E., van Ballegooijen M., Looman C. W., van Vuuren A. J., Reijerink J. C., Habbema J. D., Essink-Bot M. L., Kuipers E. J. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010; 46 (11): 2059–2066.Hol L., de Jonge V., van Leerdam M. E., van Ballegooijen M., Looman C. W., van Vuuren A. J., Reijerink J. C., Habbema J. D., Essink-Bot M. L., Kuipers E. J. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010; 46 (11): 2059–2066.Hol L., de Jonge V., van Leerdam M. E., van Ballegooijen M., Looman C. W., van Vuuren A. J., Reijerink J. C., Habbema J. D., Essink-Bot M. L., Kuipers E. J. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010; 46 (11): 2059–2066.Hol L., de Jonge V., van Leerdam M. E., van Ballegooijen M., Looman C. W., van Vuuren A. J., Reijerink J. C., Habbema J. D., Essink-Bot M. L., Kuipers E. J. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Eur J Cancer. 2010; 46 (11): 2059–2066.Hol L., Kuipers E. J., van Ballegooijen M., van Vuuren A. J., Reijerink J. C., Habbema D. J., van Leerdam M. E. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer. 2012; 130 (9): 2096–2102.Hol L., Kuipers E. J., van Ballegooijen M., van Vuuren A. J., Reijerink J. C., Habbema D. J., van Leerdam M. E. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer. 2012; 130 (9): 2096–2102.Hol L., Kuipers E. J., van Ballegooijen M., van Vuuren A. J., Reijerink J. C., Habbema D. J., van Leerdam M. E. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer. 2012; 130 (9): 2096–2102.Hol L., Kuipers E. J., van Ballegooijen M., van Vuuren A. J., Reijerink J. C., Habbema D. J., van Leerdam M. E. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer. 2012; 130 (9): 2096–2102.Hol L., Kuipers E. J., van Ballegooijen M., van Vuuren A. J., Reijerink J. C., Habbema D. J., van Leerdam M. E. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer. 2012; 130 (9): 2096–2102.Hol L., Kuipers E. J., van Ballegooijen M., van Vuuren A. J., Reijerink J. C., Habbema D. J., van Leerdam M. E. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer. 2012; 130 (9): 2096–2102.Scholefield J. H., Moss S., Sufi F., Mangham C. M., Hardcastle J. D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002; 50 (6): 840–844.Scholefield J. H., Moss S., Sufi F., Mangham C. M., Hardcastle J. D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002; 50 (6): 840–844.Scholefield J. H., Moss S., Sufi F., Mangham C. M., Hardcastle J. D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002; 50 (6): 840–844.Scholefield J. H., Moss S., Sufi F., Mangham C. M., Hardcastle J. D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002; 50 (6): 840–844.Scholefield J. H., Moss S., Sufi F., Mangham C. M., Hardcastle J. D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002; 50 (6): 840–844.Scholefield J. H., Moss S., Sufi F., Mangham C. M., Hardcastle J. D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002; 50 (6): 840–844.European Colorectal Cancer Screening Guidelines Working Group, von Karsa L. J., Patnick N., Segnan W., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. Overview: European guidelines for quality assurance in CRC screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1): 51–59.European Colorectal Cancer Screening Guidelines Working Group, von Karsa L. J., Patnick N., Segnan W., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. Overview: European guidelines for quality assurance in CRC screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1): 51–59.European Colorectal Cancer Screening Guidelines Working Group, von Karsa L. J., Patnick N., Segnan W., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. Overview: European guidelines for quality assurance in CRC screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1): 51–59.European Colorectal Cancer Screening Guidelines Working Group, von Karsa L. J., Patnick N., Segnan W., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. Overview: European guidelines for quality assurance in CRC screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1): 51–59.European Colorectal Cancer Screening Guidelines Working Group, von Karsa L. J., Patnick N., Segnan W., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. Overview: European guidelines for quality assurance in CRC screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1): 51–59.European Colorectal Cancer Screening Guidelines Working Group, von Karsa L. J., Patnick N., Segnan W., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. Overview: European guidelines for quality assurance in CRC screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1): 51–59.Vilkin A., Rozen P., Levi Z., Waked A., Maoz E., Birkenfeld S., Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100 (11): 2519–2525.Vilkin A., Rozen P., Levi Z., Waked A., Maoz E., Birkenfeld S., Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100 (11): 2519–2525.Vilkin A., Rozen P., Levi Z., Waked A., Maoz E., Birkenfeld S., Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100 (11): 2519–2525.Vilkin A., Rozen P., Levi Z., Waked A., Maoz E., Birkenfeld S., Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100 (11): 2519–2525.Vilkin A., Rozen P., Levi Z., Waked A., Maoz E., Birkenfeld S., Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100 (11): 2519–2525.Vilkin A., Rozen P., Levi Z., Waked A., Maoz E., Birkenfeld S., Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100 (11): 2519–2525.Chissov V. I., Sergeyeva N. S., Zenkina Ye. V., Marshutina N. V. Evolution of copro-tests in active detection of colorectal cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012; 22 (6): 44–52. (Russian).Chissov V. I., Sergeyeva N. S., Zenkina Ye. V., Marshutina N. V. Evolution of copro-tests in active detection of colorectal cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012; 22 (6): 44–52. (Russian).Chissov V. I., Sergeyeva N. S., Zenkina Ye. V., Marshutina N. V. Evolution of copro-tests in active detection of colorectal cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012; 22 (6): 44–52. (Russian).Chissov V. I., Sergeyeva N. S., Zenkina Ye. V., Marshutina N. V. Evolution of copro-tests in active detection of colorectal cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012; 22 (6): 44–52. (Russian).Chissov V. I., Sergeyeva N. S., Zenkina Ye. V., Marshutina N. V. Evolution of copro-tests in active detection of colorectal cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012; 22 (6): 44–52. (Russian).Chissov V. I., Sergeyeva N. S., Zenkina Ye. V., Marshutina N. V. Evolution of copro-tests in active detection of colorectal cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012; 22 (6): 44–52. (Russian).Decker K. M., Demers A. A., Nugent Z., iswanger N., Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. Am. J. Gastroenterol. 2015; 110 (12):1640–1646.Decker K. M., Demers A. A., Nugent Z., iswanger N., Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. Am. J. Gastroenterol. 2015; 110 (12):1640–1646.Decker K. M., Demers A. A., Nugent Z., iswanger N., Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. Am. J. Gastroenterol. 2015; 110 (12):1640–1646.Decker K. M., Demers A. A., Nugent Z., iswanger N., Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. Am. J. Gastroenterol. 2015; 110 (12):1640–1646.Decker K. M., Demers A. A., Nugent Z., iswanger N., Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. Am. J. Gastroenterol. 2015; 110 (12):1640–1646.Decker K. M., Demers A. A., Nugent Z., iswanger N., Singh H. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program. Am. J. Gastroenterol. 2015; 110 (12):1640–1646.Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95 (12): 6870–6875.Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95 (12): 6870–6875.Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95 (12): 6870–6875.Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95 (12): 6870–6875.Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95 (12): 6870–6875.Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95 (12): 6870–6875.Minimal'nye klinicheskie rekomendatsii Evropeiskogo Obshchestva Meditsinskoi Onkologii (ESMO). Redaktory russkogo perevoda: S. A. Tyulyandin, D. A. Nosov, N. I. Perevodchikova. Moscow, 2010. (Russian).Minimal'nye klinicheskie rekomendatsii Evropeiskogo Obshchestva Meditsinskoi Onkologii (ESMO). Redaktory russkogo perevoda: S. A. Tyulyandin, D. A. Nosov, N. I. Perevodchikova. Moscow, 2010. (Russian).Minimal'nye klinicheskie rekomendatsii Evropeiskogo Obshchestva Meditsinskoi Onkologii (ESMO). Redaktory russkogo perevoda: S. A. Tyulyandin, D. A. Nosov, N. I. Perevodchikova. Moscow, 2010. (Russian).Minimal'nye klinicheskie rekomendatsii Evropeiskogo Obshchestva Meditsinskoi Onkologii (ESMO). Redaktory russkogo perevoda: S. A. Tyulyandin, D. A. Nosov, N. I. Perevodchikova. Moscow, 2010. (Russian).Minimal'nye klinicheskie rekomendatsii Evropeiskogo Obshchestva Meditsinskoi Onkologii (ESMO). Redaktory russkogo perevoda: S. A. Tyulyandin, D. A. Nosov, N. I. Perevodchikova. Moscow, 2010. (Russian).Minimal'nye klinicheskie rekomendatsii Evropeiskogo Obshchestva Meditsinskoi Onkologii (ESMO). Redaktory russkogo perevoda: S. A. Tyulyandin, D. A. Nosov, N. I. Perevodchikova. Moscow, 2010. (Russian).Christie M., Jorissen R. N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I. T., Mc-Laughlin S., Ward R. L., Hawkins N. J., Ruszkiewicz A. R., Moore J., Burgess A. W., Busam D., Zhao Q., Strausberg R. L., Simpson A. J., Tomlinson I. P., Gibbs P., Sieber O. M. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013; 32 (39): 4675–4682.Christie M., Jorissen R. N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I. T., Mc-Laughlin S., Ward R. L., Hawkins N. J., Ruszkiewicz A. R., Moore J., Burgess A. W., Busam D., Zhao Q., Strausberg R. L., Simpson A. J., Tomlinson I. P., Gibbs P., Sieber O. M. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013; 32 (39): 4675–4682.Christie M., Jorissen R. N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I. T., Mc-Laughlin S., Ward R. L., Hawkins N. J., Ruszkiewicz A. R., Moore J., Burgess A. W., Busam D., Zhao Q., Strausberg R. L., Simpson A. J., Tomlinson I. P., Gibbs P., Sieber O. M. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013; 32 (39): 4675–4682.Christie M., Jorissen R. N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I. T., Mc-Laughlin S., Ward R. L., Hawkins N. J., Ruszkiewicz A. R., Moore J., Burgess A. W., Busam D., Zhao Q., Strausberg R. L., Simpson A. J., Tomlinson I. P., Gibbs P., Sieber O. M. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013; 32 (39): 4675–4682.Christie M., Jorissen R. N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I. T., Mc-Laughlin S., Ward R. L., Hawkins N. J., Ruszkiewicz A. R., Moore J., Burgess A. W., Busam D., Zhao Q., Strausberg R. L., Simpson A. J., Tomlinson I. P., Gibbs P., Sieber O. M. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013; 32 (39): 4675–4682.Christie M., Jorissen R. N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I. T., Mc-Laughlin S., Ward R. L., Hawkins N. J., Ruszkiewicz A. R., Moore J., Burgess A. W., Busam D., Zhao Q., Strausberg R. L., Simpson A. J., Tomlinson I. P., Gibbs P., Sieber O. M. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013; 32 (39): 4675–4682.Egorenkov V. V., Moiseenko F. V. Skrining raka tolstoi kishki. Prakticheskaya onkologiya. 2010; 11 (2): 81–87. (Russian).Egorenkov V. V., Moiseenko F. V. Skrining raka tolstoi kishki. Prakticheskaya onkologiya. 2010; 11 (2): 81–87. (Russian).Egorenkov V. V., Moiseenko F. V. Skrining raka tolstoi kishki. Prakticheskaya onkologiya. 2010; 11 (2): 81–87. (Russian).Egorenkov V. V., Moiseenko F. V. Skrining raka tolstoi kishki. Prakticheskaya onkologiya. 2010; 11 (2): 81–87. (Russian).Egorenkov V. V., Moiseenko F. V. Skrining raka tolstoi kishki. Prakticheskaya onkologiya. 2010; 11 (2): 81–87. (Russian).Egorenkov V. V., Moiseenko F. V. Skrining raka tolstoi kishki. Prakticheskaya onkologiya. 2010; 11 (2): 81–87. (Russian).Robertson C., Church S. W., Nagar H. A., Price J., Hall P. A., Russell S. E. Properties of Septin9 isoforms and the requirement for GTP binding. J Pathol. 2004; 203 (1): 519–527.Robertson C., Church S. W., Nagar H. A., Price J., Hall P. A., Russell S. E. Properties of Septin9 isoforms and the requirement for GTP binding. J Pathol. 2004; 203 (1): 519–527.Robertson C., Church S. W., Nagar H. A., Price J., Hall P. A., Russell S. E. Properties of Septin9 isoforms and the requirement for GTP binding. J Pathol. 2004; 203 (1): 519–527.Robertson C., Church S. W., Nagar H. A., Price J., Hall P. A., Russell S. E. Properties of Septin9 isoforms and the requirement for GTP binding. J Pathol. 2004; 203 (1): 519–527.Robertson C., Church S. W., Nagar H. A., Price J., Hall P. A., Russell S. E. Properties of Septin9 isoforms and the requirement for GTP binding. J Pathol. 2004; 203 (1): 519–527.Robertson C., Church S. W., Nagar H. A., Price J., Hall P. A., Russell S. E. Properties of Septin9 isoforms and the requirement for GTP binding. J Pathol. 2004; 203 (1): 519–527.De Vos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K. V., Grützmann R., Pilarsky C., Habermann J. K., Fleshner P. R., Oubre B. M., Day R., Sledziewski A. Z., Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 2009; 55 (7): 1337–1346.De Vos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K. V., Grützmann R., Pilarsky C., Habermann J. K., Fleshner P. R., Oubre B. M., Day R., Sledziewski A. Z., Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 2009; 55 (7): 1337–1346.De Vos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K. V., Grützmann R., Pilarsky C., Habermann J. K., Fleshner P. R., Oubre B. M., Day R., Sledziewski A. Z., Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 2009; 55 (7): 1337–1346.De Vos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K. V., Grützmann R., Pilarsky C., Habermann J. K., Fleshner P. R., Oubre B. M., Day R., Sledziewski A. Z., Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 2009; 55 (7): 1337–1346.De Vos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K. V., Grützmann R., Pilarsky C., Habermann J. K., Fleshner P. R., Oubre B. M., Day R., Sledziewski A. Z., Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 2009; 55 (7): 1337–1346.De Vos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K. V., Grützmann R., Pilarsky C., Habermann J. K., Fleshner P. R., Oubre B. M., Day R., Sledziewski A. Z., Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 2009; 55 (7): 1337–1346.Heichman K. A., Warren J. D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med.2012; 50 (10): 1707–1721.Heichman K. A., Warren J. D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med.2012; 50 (10): 1707–1721.Heichman K. A., Warren J. D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med.2012; 50 (10): 1707–1721.Heichman K. A., Warren J. D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med.2012; 50 (10): 1707–1721.Heichman K. A., Warren J. D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med.2012; 50 (10): 1707–1721.Heichman K. A., Warren J. D. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med.2012; 50 (10): 1707–1721.

The authors declare that there are no conflicts of interest present.